Pasar al contenido principal

BASES MOLECULARES DE PATOLOGIAS ASOCIADAS A CANALES DE CLORURO CLC Y LRRC8

SAF2015-70377-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario UNIVERSIDAD DE BARCELONA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Investigation of LRRC8-Mediated Volume-Regulated Anion Currents in Xenopus Oocytes

  • Gaitan Peñas, Hector|||0000-0001-9797-903X
  • Gradogna, Antonella
  • Laparra-Cuervo, Lara
  • Solsona, Carles
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Barrallo Gimeno, Alejandro|||0000-0003-2086-8926
  • Ciruela, Francisco|||0000-0003-0832-3739
  • Lakadamyali, Melike
  • Estévez, Raúl|||0000-0003-1579-650X
Volume-regulated anion channels (VRACs) play an important role in controlling cell volume by opening upon cell swelling. Recent work has shown that heteromers of LRRC8A with other LRRC8 members (B, C, D, and E) form the VRAC. Here, we used Xenopus oocytes as a simple system to study LRRC8 proteins. We discovered that adding fluorescent proteins to the C-terminus resulted in constitutive anion channel activity. Using these constructs, we reproduced previous findings indicating that LRRC8 heteromers mediate anion and osmolyte flux with subunit-dependent kinetics and selectivity. Additionally, we found that LRRC8 heteromers mediate glutamate and ATP flux and that the inhibitor carbenoxolone acts from the extracellular side, binding to probably more than one site. Our results also suggest that the stoichiometry of LRRC8 heteromers is variable, with a number of subunits ≥6, and that the heteromer composition depends on the relative expression of different subunits. The system described here enables easy structure-function analysis of LRRC8 proteins.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Leukoencephalopathy-causing CLCN2 mutations are associated with impaired Cl- channel function and trafficking

  • Gaitan Peñas, Hector|||0000-0001-9797-903X
  • Apaja, Pirjo M
  • Arnedo, Tanit
  • Castellanos, Aida
  • Elorza-Vidal, Xabier
  • Soto, David
  • Gasull, Xavier|||0000-0002-6154-8323
  • Lukacs, Gergely L
  • Estévez, Raúl|||0000-0003-1579-650X
Key points: Characterisation of most mutations found in CLCN2 in patients with CC2L leukodystrophy show that they cause a reduction in function of the chloride channel ClC-2. GlialCAM, a regulatory subunit of ClC-2 in glial cells and involved in the leukodystrophy megalencephalic leukoencephalopathy with subcortical cysts (MLC), increases the activity of a ClC-2 mutant by affecting ClC-2 gating and by stabilising the mutant at the plasma membrane. The stabilisation of ClC-2 at the plasma membrane by GlialCAM depends on its localisation at cell-cell junctions. The membrane protein MLC1, which is defective in MLC, also contributes to the stabilisation of ClC-2 at the plasma membrane, providing further support for the view that GlialCAM, MLC1 and ClC-2 form a protein complex in glial cells. Abstract: Mutations in CLCN2 have been recently identified in patients suffering from a type of leukoencephalopathy involving intramyelinic oedema. Here, we characterised most of these mutations that reduce the function of the chloride channel ClC-2 and impair its plasma membrane (PM) expression. Detailed biochemical and electrophysiological analyses of the Ala500Val mutation revealed that defective gating and increased cellular and PM turnover contributed to defective A500V-ClC-2 functional expression. Co-expression of the adhesion molecule GlialCAM, which forms a tertiary complex with ClC-2 and megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1), rescued the functional expression of the mutant by modifying its gating properties. GlialCAM also restored the PM levels of the channel by impeding its turnover at the PM. This rescue required ClC-2 localisation to cell-cell junctions, since a GlialCAM mutant with compromised junctional localisation failed to rescue the impaired stability of mutant ClC-2 at the PM. Wild-type, but not mutant, ClC-2 was also stabilised by MLC1 overexpression. We suggest that leukodystrophy-causing CLCN2 mutations reduce the functional expression of ClC-2, which is partly counteracted by GlialCAM/MLC1-mediated increase in the gating and stability of the channel.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CLCN1 Myotonia congenita mutation with a variable pattern of inheritance suggests a novel mechanism of dominant myotonia

  • Gaitan Peñas, Hector|||0000-0001-9797-903X
  • Armand-Ugón, Mercedes|||0000-0002-4069-9915
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
Introduction: Mutations in CLCN1 cause recessive or dominant forms of myotonia congenita (MC). Some mutations have been found to exhibit both patterns of inheritance but the mechanism explaining this behavior is unknown. Methods: A known recessive missense mutation, A493E, was identified in a family with dominant MC. The mutant p.A493E alone or in co-expression with wild-type (WT) ClC-1 was expressed in Xenopus oocytes. Currents were measured and biochemical assays were performed. Results: The mutant showed no significant activity and reduced total and plasma membrane (PM) protein levels. Co-expression with the mutant reduced the activity and PM levels of an engineered lower expression variant of ClC-1, whereas no effect was observed on a higher expression variant. Discussion: Our results suggest that the dominant effect of some CLCN1 mutations showing recessive or dominant inheritance patterns may be due to a dose-dependent defect in PM delivery of the WT channel. Muscle Nerve 58: 157-160, 2018.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Megalencephalic leukoencephalopathy with subcortical cysts: a personal biochemical retrospective

  • Estévez, Raúl
  • Elorza-Vidal, Xabier
  • Gaitán-Peñas, Héctor
  • Pérez-Rius, Carla
  • Armand-Ugón, Mercedes
  • Alonso-Gardón, Marta
  • Xicoy-Espaulella, Efren
  • Sirisi, Sònia
  • Arnedo, Tanit
  • Capdevila-Nortes, Xavier
  • López-Hernández, Tania
  • Montolio, Marisol
  • Duarri, Anna
  • Teijido Hermida, Óscar
  • Barrallo-Gimeno, Alejandro
  • Palacín, Manuel
  • Nunes, Virginia
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy characterized by dysfunction of the role of glial cells in controlling brain fluid and ion homeostasis. Patients affected by MLC present macrocephaly, cysts and white matter vacuolation, which lead to motor and cognitive impairments. To date, there is no treatment for MLC, only supportive care. MLC is caused by mutations in the MLC1 and GLIALCAM genes. MLC1 is a membrane protein with low identity to the Kv1.1 potassium channel and GlialCAM belongs to an adhesion molecule family. Both proteins form a complex with an as-yet-unknown function that is expressed mainly in the astrocytes surrounding the blood-brain barrier and in Bergmann glia. GlialCAM also acts as an auxiliary subunit of the chloride channel ClC-2, thus regulating its localization at cell-cell junctions and modifying its functional properties by affecting the common gate of ClC-2. Recent studies in Mlc1-, GlialCAM- and Clcn2-knockout mice or Mlc1-knockout zebrafish have provided fresh insight into the pathophysiology of MLC and further details about the molecular interactions between these three proteins. Additional studies have shown that GlialCAM/MLC1 also regulates other ion channels (TRPV4, VRAC) or transporters (Na+/K+-ATPase) in a not-understood manner. Furthermore, it has been shown that GlialCAM/ MLC1 may influence signal transduction mechanisms, thereby affecting other proteins not related with transport such as the EGF receptor. Here, we offer a personal biochemical retrospective of the work that has been performed to gain knowledge of the pathophysiology of MLC, and we discuss future strategies that may be used to identify therapeutic solutions for MLC patients., This work was supported in part by grants from the European Leukodystrophies Association (ELA) Research Foundation (ELA2012- 014C2B) to RE and VN, Ministerio de Ciencia e Innovación (SAF2012-31486 to RE and SAF2015-70377 to RE and ABG), Generalitat de Catalunya ((SGR2014-1178) to RE), (SGR2014-541) to VN)), Instituto de Salud Carlos III (bodies linked to MICINN and FEDER): (ERARE) to RE, FIS PI13/00121 to VN.